How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...
Forecasts of explosive AI progress predict that what researchers call recursive self-improvement is on the horizon. But a ...
I tried to use one app for everything, then I realized that was the problem ...
Architecting with portability in mind is the best way to minimize lock-in as AI pricing models evolve. Price hikes are inevitable.
On September 8, at Goldman Sachs’ Communacopia conference, OpenAI CFO Sarah Friar confirmed that the company utilized its own frontier AI models to design the Jalapeno custom inference chip. This ...
This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed. The above button links to ...
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results